出版社:Grupo de Pesquisa Metodologias em Ensino e Aprendizagem em Ciências
摘要:Objective: To carry out a complete economic analysis of the cost-effectiveness of the most used treatments for osteosarcoma in cancer patients aged 0-19 years. Methods: The economic analysis was carried out from the manager’s perspective and used the decision tree model. Effectiveness was measured through the ratio of the prevalence of not dying and data were taken from the Hospital Cancer Registry (RHC). The costs were obtained from the Management System of the Table of Procedures and Orthotics, Prosthetics and Special Materials (OPM) - (SIGTAP) of the Unified Health System (SUS) in a 20-year time frame (1997-2017). Results: For the 1,957 registered cases, the most used treatments were surgery associated with chemotherapy (50.43%) and only with chemotherapy (39.20%). Complete remission had higher percentages in cases treated only with surgery (36.95%) and the highest percentages of death were observed in treatment only with chemotherapy (29.73%). The Chemotherapy+Surgery association was not cost-effective, having a higher incremental cost (R$ 7,285.83) and lower incremental effectiveness (-0.13%). Surgery was considered an indispensable therapy, as it showed greater effectiveness compared to other treatments. Conclusion: Surgery was the most cost-effective treatment option.